These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14722274)

  • 1. Rapid production of neutralizing antibody leads to transient hepadnavirus infection.
    Zhang YY; Summers J
    J Virol; 2004 Feb; 78(3):1195-201. PubMed ID: 14722274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
    Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
    Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
    Miller DS; Halpern M; Kotlarski I; Jilbert AR
    Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spread of hepatitis B viruses in vitro requires extracellular progeny and may be codetermined by polarized egress.
    Funk A; Hohenberg H; Mhamdi M; Will H; Sirma H
    J Virol; 2004 Apr; 78(8):3977-83. PubMed ID: 15047813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The early host innate immune response to duck hepatitis B virus infection.
    Tohidi-Esfahani R; Vickery K; Cossart Y
    J Gen Virol; 2010 Feb; 91(Pt 2):509-20. PubMed ID: 19846670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
    Jilbert AR; Botten JA; Miller DS; Bertram EM; Hall PM; Kotlarski J; Burrell CJ
    Virology; 1998 May; 244(2):273-82. PubMed ID: 9601498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
    Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
    J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective efficacy of DNA vaccines against duck hepatitis B virus infection.
    Triyatni M; Jilbert AR; Qiao M; Miller DS; Burrell CJ
    J Virol; 1998 Jan; 72(1):84-94. PubMed ID: 9420203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
    Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
    Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of surgical immunomodulation on liver inflammation and clearance of DHBV infection.
    Vickery K; Tohidi-Esfahani R; Pouliopoulos J; Welschinger R; Dixon R; Deva A; Cossart Y
    J Med Virol; 2006 Dec; 78(12):1572-8. PubMed ID: 17063509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection.
    Narayan R; Buronfosse T; Schultz U; Chevallier-Gueyron P; Guerret S; Chevallier M; Saade F; Ndeboko B; Trepo C; Zoulim F; Cova L
    J Gen Virol; 2006 Nov; 87(Pt 11):3225-3232. PubMed ID: 17030856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
    Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
    Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement.
    Jilbert AR; Wu TT; England JM; Hall PM; Carp NZ; O'Connell AP; Mason WS
    J Virol; 1992 Mar; 66(3):1377-88. PubMed ID: 1738197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to duck hepatitis B virus infection.
    Jilbert AR; Kotlarski I
    Dev Comp Immunol; 2000; 24(2-3):285-302. PubMed ID: 10717294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DHBV manipulation and prediction of the outcome of infection.
    Vickery K; Cossart Y
    J Hepatol; 1996 Oct; 25(4):504-9. PubMed ID: 8912150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocytes traffic and export hepatitis B virus basolaterally by polarity-dependent mechanisms.
    Bhat P; Snooks MJ; Anderson DA
    J Virol; 2011 Dec; 85(23):12474-81. PubMed ID: 21937643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.
    Khawaja G; Buronfosse T; Jamard C; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans C; Hartmann D; Cova L
    Virology; 2012 Mar; 425(1):61-9. PubMed ID: 22284894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of duck hepatitis B virus infection of liver cells by combined treatment with viral e antigen and carbohydrates.
    Maenz C; Loscher C; Iwanski A; Bruns M
    J Gen Virol; 2008 Dec; 89(Pt 12):3016-3026. PubMed ID: 19008388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral effects of PNA in duck hepatitis B virus infection model.
    Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
    Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous replacement of the supposed host determining region of avihepadnaviruses: high in vivo infectivity despite low infectivity for hepatocytes.
    Dallmeier K; Schultz U; Nassal M
    PLoS Pathog; 2008 Dec; 4(12):e1000230. PubMed ID: 19057662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.